NDRG2 gene expression pattern in ovarian cancer and its specific roles in inhibiting cancer cell proliferation and suppressing cancer cell apoptosis

CURRENT STATUS: UNDER REVIEW

Journal of Ovarian Research  ■ BMC

Fenhong Kang
Women and Children's Hospital, School of Medicine, Xiamen University

Yanlong Wang
Women and Children's Hospital, School of Medicine, Xiamen University

Yaping Luo  ly76700@163.com
Women and Children's Hospital, School of Medicine, Xiamen University
Corresponding Author
ORCiD: 0000-0002-0807-7032

Yongjun Zhang
Zhongshan Hospital, Xiamen University

DOI: 10.21203/rs.2.20090/v1

SUBJECT AREAS  Obstetrics & Gynecology  Cancer Biology

KEYWORDS
ovarian cancer, N-myc downstream-regulated gene 2 (NDRG2), cell viability, apoptosis, cisplatin (DDP)
Abstract

Background The cancer cell metastasis and the acquisition of chemotherapy resistance remain huge challenge for ovarian cancer treatment. Previously, N-myc downstream-regulated gene 2 (NDRG2) serves as a tumor suppressor for many cancers. Here, we attempted to investigate the specific roles of NDRG2 in ovarian cancer.

Methods The expression levels of NDRG2 were detected by qRT-PCR or Immunoblotting assay. CCK-8 assay was employed to examine the cell viability of ovarian cancer cells. The colony formation ability was determined by colony formation assay. Flow cytometry analyses were performed to detect the cell apoptosis and cell cycle.

Results Herein, we revealed that NDRG2 mRNA expression and protein levels were downregulated within both ovarian cancer tissues and cell lines. The overexpression of NDRG2 dramatically inhibited the cell viability and colony formation, whereas promoted the cell apoptosis and cell cycle arrest in G1 phase within ovarian cancer cells. More importantly, NDRG2 overexpression significantly enhanced the suppressive roles of cisplatin (DDP) in ovarian cancer cell viability. On the contrary, NDRG2 silence exerted opposing effects on ovarian cancer cells.

Conclusions In summary, we provide a solid experimental basis demonstrating the tumor-suppressive effects of NDRG2 in inhibiting the cell proliferation, enhancing the cell apoptosis, eliciting the cell cycle arrest in G1 phase, and promoting the suppressive effects of DDP on the viability of ovarian cancer cells. NDRG2 administration presents a potent adjuvant treatment for ovarian cancer therapy, which needs further in vivo and clinical investigation.
Introduction

Ovarian cancer is one of the deadliest malignancies in female [1, 2]. Since the incipient symptoms of ovarian cancer are obscure, most patients received diagnosis until entering the advanced stage [3–5]. Surgical treatment and platinum-based chemotherapy are major therapeutic strategies for ovarian cancers [6]. Unfortunately, these therapeutic methods seem to become less effective with the progression of the cancer. Moreover, the morbidity of the ovarian cancer also remains a higher level due to lack of reliable predictive biomarker, ovarian cancer cells metastasis and the resistance to chemotherapy [7]. Thus, it’s necessary to determine ovarian cancer pathophysiology and find new treatment methods. Interestingly, it has been revealed the correlations between cancer (such as lung, prostate, liver, colorectal and breast cancer) and N-myc downstream-regulated gene 2 (NDRG2) [8–10]. NDRG2 is considered to be a tumor suppressor which contributes to not only hormone, ion, fluid metabolism and other cellular metabolic processes [11, 12], but also stress responses, like those under hypoxic environments and lipid toxicity [13, 14]. It has been demonstrated the correlations between NDRG2 and cancer within neurotumors [15, 16], gastroenteric tumors [9, 17], genitourinary tumors [18, 19], breast carcinoma [20, 21], lung carcinoma [10, 22], thyroid carcinoma [23], oral squamous-cell cancer [24], myeloid leukemia [25], and cervical cancer [14]. Collectively, the expression of NDRG2 is reduced within human tumors, while its overexpression suppresses the capacity of cancer cells to proliferate, migrate, metabolize and invade [26]; NDRG2 expression levels are negatively correlated with human cancer clinical and pathological conditions [26]. Nevertheless, little is known about the specific role of NDRG2 within ovarian cancer. Herein, NDRG2 mRNA and protein expression showed to be monitored within ovarian
cancer tissues and cells. Next, NDRG2 overexpression and silence were conducted in three cell lines of ovarian cancer; the specific effects of NDRG2 upon the viability, colony formation ability, apoptosis, cell cycle, and the sensitivity to cisplatin (DDP) treatment of ovarian cancer cells were evaluated. In summary, we attempt to provide a solid experimental basis for understanding the cellular functions of NDRG2 on ovarian cancer cells.

Materials and methods

Clinical tissue samples

We collected a total of 6 paired non-cancerous (NC) and ovarian cancer tissues from patients received resection surgeries in Zhongshan hospital with the signed the consent from each patient. All the experiments in the present study were conducted with the approval of the Ethics Committee of Zhongshan hospital. The pathologic type of all samples was confirmed by two independent pathological experts. Tissues were frozen at -80°C immediately after sampling until further use.

Cell lines and cell culture

A normal cell line, human ovarian surface epithelial cell line (HOSE, also known as HOSEpiC), was purchased from ScienCell (Cat. #7310; Carlsbad, CA, USA) and cultured in Ovarian Epithelial Cell Medium (OEpiCM, Cat. #7311; ScienCell). Ovarian cancer SKOV3 (ATCC® HTB-77™), OVCAR-3 (ATCC® HTB-161™), and CAOV3 (ATCC® HTB-75™) cell lines were obtained from ATCC (Manassas, VA, USA). SKOV3 cells were cultured in McCoy's 5a Medium Modified (Catalog No. 30-2007; ATCC). CAOV3 cells were cultured in Dulbecco's Modified Eagle's Medium (Catalog No. 30-2002; ATCC). OVCAR-3 cells were cultured in RPMI-1640 Medium (Catalog No. 30-2001; ATCC). All the cells were cultured with 10% FBS (Invitrogen, Carlsbad, CA, USA) at
37°C in 5% CO₂.

Cells were transfected with scramble siRNA (negative control, si-NC; RiboBio, Guangzhou, China) or NDRG2 siRNA (si-NDRG2; RiboBio) with the help of Lipofectamine 3000 reagent (Thermo Fisher Scientific, Waltham, MA, USA). Cells were collected and used for further experiments 48 h after transfection.

**PCR-based analyses**

Total RNA was extracted from target cells with the help of TRizol reagent (Invitrogen). The reverse transcription of extracted RNAs into cDNA was performed with the help of Maxima First Strand cDNA Synthesis Kits (K1672; Thermo Fisher).

The expression of mRNA was determined with an SYBR® Green Real-time PCR Master Mix (Sigma, St. Louis, MO, USA) using GAPDH as an endogenous control. All the results were processed and analyzed using the 2\(^{-\Delta\Delta CT}\) method.

**Immunoblotting**

Cell lysate was prepared using RIPA lysis buffer (Applygen, Beijing, China) and proteins were extracted. SDS-PAGE (10%) was used to separate the extracted proteins. After that, proteins were transferred onto PVDF membranes. Nonspecific antigen was blocked by 5% non-fat milk solution, and the membranes were washed three times using PBST. The membranes were then incubated overnight at 4°C with anti-NDRG2 (12015-1-AP, Proteintech, Rosemont, IL, USA) and anti-β-actin (60008-1-Ig, Proteintech). After washing with PBST, the membranes were incubated with appropriate HRP goat anti-mouse/anti-rabbit IgG (Proteintech) at room temperature. The visualization of all the blots were conducted using enhanced chemiluminescence (ECL; Thermo Fisher).

**Cell viability determined by CCK-8 assay**
A CCK-8 kit (Sigma-Aldrich) was employed to examine the cell viability of ovarian cancer cell lines in response to different treatment and/or transfection. Cells were placed into 96-well plates at a density of $1 \times 10^4$ cells/well. CCK-8 solution was added at 0 h and 24 h thereafter and then cells were incubated for 4 h at 37°C. The absorbance (OD value) was measured at 450 nm.

**Colony formation**

The colony formation ability was determined. Cells were cultured 6-well plates at a density of $1 \times 10^2$ cells/well. Fourteen days later, the colonies were fixed with methanol and stained with 0.1% crystal violet (Sigma-Aldrich, St. Louis, MO, USA). After that, the number of visible colonies were counted.

**Cell cycle and cell apoptosis determined by Flow cytometry**

Flow cytometry analyses were performed to detect the cell apoptosis and cell cycle. For cell apoptosis analysis, cells were collected, resuspended, and added with annexin V-FITC and PI. After 15 min of incubation, the cell apoptosis was analyzed. For cell cycle analysis, cells were fixed with ethanol (70%, ice-cold) for 20 min and added with PI. After 20 min incubation, the cell cycle was analyzed.

**Data processing and statistical analysis**

All data collected from three independent experiments were processed and analyzed by GraphPad (San Diego, CA, USA). The data was represented as mean ± SD. The comparison was conducted using paired or unpaired Student’s t-test. A $P$ value of less than 0.05 was considered as statistically significant.

**Results**

**The mRNA and protein expression of NDRG2 within tissues and cells**

To further confirm how NDRG2 affected ovarian cancer, we first verified NDRG2
expression within the tissues and cells of ovarian cancer. The mRNA expression of NDRG2 showed to be dramatically downregulated within ovarian cancer tissues than that in non-cancerous tissue samples (Fig.1A); similarly, the mRNA expression of NDRG2 also showed to be remarkably downregulated within three ovarian cancer cells, SKOV3, OVCAR-3, and CAOV3, than that in a normal cell line, HOSE (Fig.1C). Consistently, NDRG2 protein levels were decreased within ovarian cancer tissues than those in non-cancerous tissue samples (Fig.1B), and decreased in SKOV3, OVCAR-3, and CAOV3 cells, compared to those in HOSE cells (Fig.1D).

**Involvements of NDRG2 in proliferation, apoptosis, and cell cycle of ovarian cancer cells**

To further investigate the specific effects of NDRG2 on ovarian cancer cells, we conducted NDRG2 overexpression and NDRG2 silence in SKOV3, OVCAR-3, and CAOV3 cells by transfection with vector (negative control), NDRG2 OE, si-NC (negative control), or si-NDRG3. The transfection efficiency was determined via real-time PCR (Fig.2A-B).

Next, the effects of NDRG2 overexpression and silence on ovarian cancer cells were evaluated. As revealed by CCK-8 and colony formation analyses, NDRG2 overexpression significantly suppressed, whereas NDRG2 silence promoted the cell viability and colony formation ability of SKOV3, OVCAR-3, and CAOV3 cells (Fig.3A-B). Consistently, NDRG2 overexpression significantly enhanced, whereas NDRG2 silence suppressed cell apoptosis within all the three ovarian cancer cells (Fig.4A). Moreover, NDRG2 overexpression significantly induced the cell cycle arrested in G1 phase, whereas NDRG2 silence exerted an opposing effect (Fig.4B). These data indicate that NDRG2 inhibits the cell viability and colony formation, and induces apoptosis and cell cycle arrest in G1 phase, thus acting as a tumor suppressor
Effects of NDRG2 on ovarian cancer cell sensitivity to DDP treatment

To date, DDP is one of the most valid agents of ovarian cancer and other solid tumors [27-29]. After confirming the tumor-suppressive effect of NDRG2 on ovarian cancer cells, we further investigated whether NDRG2 could sensitize ovarian cancer cells to DDP treatment. We transfected SKOV3, OVCAR-3, and CAOV3 cells with vector (negative control), NDRG2 OE, si-NC (negative control), or si-NDRG2 under DDP treatment and examined for cell viability. As shown in Fig.5, NDRG2 overexpression enhanced the suppressive role of DDP in the viability of ovarian cancer cells, whereas NDRG2 silence exerted an opposing effect. In summary, NDRG2 could improve the cellular effects of DDP on ovarian cancer cells.

Discussion

Herein, we revealed that NDRG2 mRNA expression and protein levels were downregulated within both ovarian cancer tissues and cell lines. The overexpression of NDRG2 dramatically inhibited the cell viability and colony formation, whereas promoted the cell apoptosis and cell cycle arrest in G1 phase within ovarian cancer cells. More importantly, NDRG2 overexpression significantly enhanced the suppressive roles of DDP in ovarian cancer cell viability. On the contrary, NDRG2 silence exerted opposing effects on ovarian cancer cells.

NDRG2 is one member of the NDRG family that contains NDRG1, NDRG2, NDRG3, and NDRG4 [30, 31]. NDRG2 has been reported to be reduced within colorectal cancer, liver cancer, thyroid cancer, glioblastoma, breast cancer and a number of other human cancers [16, 17, 20, 23, 32, 33]. Moreover, the increase in NDRG2 expression within cancer cells can be related to improved prognosis in gastric
cancer, high-grade glioma and hepatocellular carcinomas [17, 34, 35]. Herein, the mRNA and protein expression of NDRG2 showed to be dramatically downregulated within the ovarian cancer tissues than that in the normal controls. In vitro, the mRNA and protein expression of NDRG2 also showed to be remarkably downregulated within SKOV3, OVCAR-3, and CAOV3 cells than those within a non-cancerous ovarian epithelial cell line, HOSE. Since excessive NDRG2 protein within cancer cells leads to significantly decreased cell proliferation [16, 36, 37] while the increased mRNA expression of NDRG2 can be related to improved prognosis [17, 34], we speculate that NDRG2 might act as a tumor suppressor within ovarian cancer, possibly by regulating ovarian cancer cell proliferation and apoptosis.

To verify the above-mentioned speculation, we conducted NDRG2 overexpression or silence in ovarian cancer cells and evaluated its cellar effects. Consistent with its expression pattern, NDRG2 acts as a tumor suppressor within ovarian cancer cell lines. NDRG2 overexpression dramatically suppressed the proliferation whereas enhanced the apoptosis of ovarian cancer cells, similarly to its effects on other cancers [22, 38-40]. Besides, the resetting of the G1, S, G2, M phases and other cell cycles can be found in the occurrence and development of tumors. As confirmed by a GO (Gene Ontology) enrichment analysis on the biological process, molecular function and cellular component, the overexpression of NDRG2 can increase the G protein signaling-associated genes while reduce the M phase-associated gene sets, which is consistent with cell cycle analyses [41]. Analyses on the signaling pathways have also revealed the decreased glycosylphosphatidylinositol (GPI)-anchor biosynthesis and protein degradation [41]. It has also been demonstrated by Ma et al. [19] that G1 arrest can be induced by the expression of NDRG2. NDRG2 was introduced into SW620 cells, after which the cell cycle arrest was observed to
arrest at G1/S phase [37]. The expression of NDRG2 can effectively inhibit cell cycle resetting within tumors. Herein, we observed similar results that, NDRG2 overexpression dramatically induced the cell cycle arrest in G1 phase in all the three ovarian cancer cell lines, suggesting that NDRG2 might suppress ovarian cancer cell proliferation via affecting the resetting of cancer cell cycle. Cisplatin is the most common platinum-based chemotherapy drug. Its action mechanism is DNA cross-linking, so its tumor-suppressive activity is broad-spectrum and non-cell cycle-specific, leading to the inhibition of DNA replication and transcription and induction of tumor cell apoptosis [42, 43]. Although cisplatin has been considered an effective agent for ovarian cancer treatment, the acquisition and development of drug resistance has emerged as a primary obstacle to its wide clinical application [44]. Previously, Liu et al. [45] reported that NDRG2 silence inhibits the expression of Bcl-2, so that cervical cancer Hela cells can be sensitive to cisplatin. In histiocytic lymphoma U937 cells, NDRG2 could modulate NOX5-ROS-PKR pathway-regulated Bak-to-Mcl-1 ratio to increase the sensitivity to cisplatin [46]. In the present study, NDRG2 overexpression within ovarian cancer cell lines significantly enhanced the suppressive effects of DDP upon the viability of ovarian cancer cells, whereas NDRG2 silence exerted an opposing effect. These data indicate that NDRG2 might sensitize ovarian cancer cells to DDP treatment, which needs further in vivo experimental investigation.

Conclusion

Taken together, our findings provide a solid experimental basis demonstrating the cellular effects of NDRG2 in inhibiting the cell proliferation, enhancing the cell apoptosis, eliciting the cell cycle arrest in G1 phase, and promoting the suppressive
effects of DDP upon the viability of cancer cells. Nevertheless, it is still necessary to further study the new strategy of rescuing the abnormally downregulated NDRG2 expression as a promising therapeutic strategy for clinical applications.

Declarations

**Ethics approval and consent to participate**

All procedures performed in studies involving human participants were in accordance with the ethical standards of the Ethics Committee of Zhongshan hospital. All participants signed the informed consent.

**Consent for publication**

Not applicable.

**Availability of data and materials**

All data generated or analyzed during this study are included in this published article.

**Conflict of Interest**

The authors declare that they have no competing interest.

**Funding**

This study was supported by Youth scientific research project of Fujian Health and Family Planning Commission (2015-2-51).

**Acknowledgment**

Not applicable.

**References**

1. Liu C, Zhang Y, Jiang H, Wu H: *Association between social support and post-traumatic stress disorder symptoms among Chinese patients with*
ovarian cancer: A multiple mediation model. PLoS One 2017, 12(5):e0177055.

2. Xia B, Yang S, Liu T, Lou G: miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6. Mol Cancer 2015, 14:57.

3. Mueller JJ, Zhou QC, Iasonos A, O'Cearbhaill RE, Alvi FA, El Haraki A, Eriksson AG, Gardner GJ, Sonoda Y, Levine DA et al: Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center. Gynecol Oncol 2016, 140(3):436-442.

4. Li N, Yang L, Wang H, Yi T, Jia X, Chen C, Xu P: MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells. PLoS One 2015, 10(6):e0128886.

5. Colombo PE, Fabbro M, Theillet C, Bibeau F, Rouanet P, Ray-Coquard I: Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer. Crit Rev Oncol Hematol 2014, 89(2):207-216.

6. Kim A, Ueda Y, Naka T, Enomoto T: Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Res 2012, 31:14.

7. Gao Y, Foster R, Yang X, Feng Y, Shen JK, Mankin HJ, Hornicek FJ, Amiji MM, Duan Z: Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer. Oncotarget 2015, 6(11):9313-9326.

8. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY et al: Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic
analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380(9859):2095-2128.

9. Deuschle U, Schuler J, Schulz A, Schluter T, Kinzel O, Abel U, Kremoser C: FXR controls the tumor suppressor NDRG2 and FXR agonists reduce liver tumor growth and metastasis in an orthotopic mouse xenograft model. PLoS One 2012, 7(10):e43044.

10. Wang H, Wang W, Wang X, Cai K, Wu H, Ju Q, Huang Z, Gao X: Reduced N-Myc downstream-regulated gene 2 expression is associated with CD24 upregulation and poor prognosis in patients with lung adenocarcinoma. Med Oncol 2012, 29(5):3162-3168.

11. Ma J, Liu W, Guo H, Li S, Cao W, Du X, Lei S, Hou W, Xiong L, Yao L et al: N-myc downstream-regulated gene 2 expression is associated with glucose transport and correlated with prognosis in breast carcinoma. Breast Cancer Res 2014, 16(2):R27.

12. Li Y, Yang J, Li S, Zhang J, Zheng J, Hou W, Zhao H, Guo Y, Liu X, Dou K et al: N-myc downstream-regulated gene 2, a novel estrogen-targeted gene, is involved in the regulation of Na+/K+-ATPase. J Biol Chem 2011, 286(37):32289-32299.

13. Shen L, Liu X, Hou W, Yang G, Wu Y, Zhang R, Li X, Che H, Lu Z, Zhang Y et al: NDRG2 is highly expressed in pancreatic beta cells and involved in protection against lipotoxicity. Cell Mol Life Sci 2010, 67(8):1371-1381.

14. Liu J, Zhang J, Wang X, Li Y, Chen Y, Li K, Zhang J, Yao L, Guo G: HIF-1 and NDRG2 contribute to hypoxia-induced radioresistance of cervical cancer Hela cells. Exp Cell Res 2010, 316(12):1985-1993.

15. Li L, Wang J, Shen X, Wang L, Li X, Liu Y, Shi M, Zhao G, Deng Y: Expression
and prognostic value of NDRG2 in human astrocytomas. *J Neurol Sci* 2011, **308**(1-2):77-82.

16. Deng Y, Yao L, Chau L, Ng SS, Peng Y, Liu X, Au WS, Wang J, Li F, Ji S et al: **N-Myc downstream-regulated gene 2 (NDRG2) inhibits glioblastoma cell proliferation.** *Int J Cancer* 2003, **106**(3):342-347.

17. Lee DC, Kang YK, Kim WH, Jang YJ, Kim DJ, Park IY, Sohn BH, Sohn HA, Lee HG, Lim JS et al: **Functional and clinical evidence for NDRG2 as a candidate suppressor of liver cancer metastasis.** *Cancer Res* 2008, **68**(11):4210-4220.

18. Ren GF, Tang L, Yang AQ, Jiang WW, Huang YM: **Prognostic impact of NDRG2 and NDRG3 in prostate cancer patients undergoing radical prostatectomy.** *Histol Histopathol* 2014, **29**(4):535-542.

19. Ma JJ, Liao CG, Jiang X, Zhao HD, Yao LB, Bao TY: **NDRG2 suppresses the proliferation of clear cell renal cell carcinoma cell A-498.** *J Exp Clin Cancer Res* 2010, **29**:103.

20. Lorentzen A, Lewinsky RH, Bornholdt J, Vogel LK, Mitchelmore C: **Expression profile of the N-myc Downstream Regulated Gene 2 (NDRG2) in human cancers with focus on breast cancer.** *BMC Cancer* 2011, **11**:14.

21. Jeschke J, Van Neste L, Glockner SC, Dhir M, Calmon MF, Deregowski V, Van Criekinge W, Vlassenbroeck I, Koch A, Chan TA et al: **Biomarkers for detection and prognosis of breast cancer identified by a functional hypermethylome screen.** *Epigenetics* 2012, **7**(7):701-709.

22. Li R, Yu C, Jiang F, Gao L, Li J, Wang Y, Beckwith N, Yao L, Zhang J, Wu G: **Overexpression of N-Myc downstream-regulated gene 2 (NDRG2) regulates the proliferation and invasion of bladder cancer cells in vitro**
and in vivo. *PLoS One* 2013, **8**(10):e76689.

23. Zhao H, Zhang J, Lu J, He X, Chen C, Li X, Gong L, Bao G, Fu Q, Chen S et al: **Reduced expression of N-Myc downstream-regulated gene 2 in human thyroid cancer.** *BMC Cancer* 2008, **8**:303.

24. Furuta H, Kondo Y, Nakahata S, Hamasaki M, Sakoda S, Morishita K: **NDRG2 is a candidate tumor-suppressor for oral squamous-cell carcinoma.** *Biochem Biophys Res Commun* 2010, **391**(4):1785-1791.

25. Tschan MP, Shan D, Laedrach J, Eyholzer M, Leibundgut EO, Baerlocher GM, Tobler A, Stroka D, Fey MF: **NDRG1/2 expression is inhibited in primary acute myeloid leukemia.** *Leuk Res* 2010, **34**(3):393-398.

26. Hu W, Fan C, Jiang P, Ma Z, Yan X, Di S, Jiang S, Li T, Cheng Y, Yang Y: **Emerging role of N-myc downstream-regulated gene 2 (NDRG2) in cancer.** *Oncotarget* 2016, **7**(1):209-223.

27. Hou L, Hou X, Wang L, Li Z, Xin B, Chen J, Gao X, Mu H: **PD98059 impairs the cisplatin-resistance of ovarian cancer cells by suppressing ERK pathway and epithelial mesenchymal transition process.** *Cancer Biomark* 2017, **21**(1):187-194.

28. Kelland LR: **Emerging drugs for ovarian cancer.** *Expert Opin Emerg Drugs* 2005, **10**(2):413-424.

29. Mei L, Chen H, Wei DM, Fang F, Liu GJ, Xie HY, Wang X, Zou J, Han X, Feng D: **Maintenance chemotherapy for ovarian cancer.** *Cochrane Database Syst Rev* 2010(9):CD007414.

30. Melotte V, Qu X, Ongenaert M, van Criekinge W, de Bruine AP, Baldwin HS, van Engeland M: **The N-myc downstream regulated gene (NDRG) family: diverse functions, multiple applications.** *FASEB J* 2010, **24**(11):4153-4166.
31. Qu X, Zhai Y, Wei H, Zhang C, Xing G, Yu Y, He F: **Characterization and expression of three novel differentiation-related genes belong to the human NDRG gene family.** *Mol Cell Biochem* 2002, **229**(1-2):35-44.

32. Lorentzen A, Vogel LK, Lewinsky RH, Saebo M, Skjelbred CF, Godiksen S, Hoff G, Tveit KM, Lothe IM, Ikdahl T *et al*: **Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma.** *BMC Cancer* 2007, **7**:192.

33. Tepel M, Roerig P, Wolter M, Gutmann DH, Perry A, Reifenberger G, Riemenschneider MJ: **Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma.** *Int J Cancer* 2008, **123**(9):2080-2086.

34. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L *et al*: **Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.** *Cancer Cell* 2006, **9**(3):157-173.

35. Choi SC, Yoon SR, Park YP, Song EY, Kim JW, Kim WH, Yang Y, Lim JS, Lee HG: **Expression of NDRG2 is related to tumor progression and survival of gastric cancer patients through Fas-mediated cell death.** *Exp Mol Med* 2007, **39**(6):705-714.

36. Park Y, Shon SK, Kim A, Kim KI, Yang Y, Cho DH, Lee MS, Lim JS: **SOCS1 induced by NDRG2 expression negatively regulates STAT3 activation in breast cancer cells.** *Biochem Biophys Res Commun* 2007, **363**(2):361-367.

37. Kim YJ, Yoon SY, Kim JT, Choi SC, Lim JS, Kim JH, Song EY, Lee HG, Choi I, Kim JW: **NDRG2 suppresses cell proliferation through down-regulation of AP-1 activity in human colon carcinoma cells.** *Int J Cancer* 2009, **124**(1):7-15.
38. Ma J, Liu W, Yan X, Wang Q, Zhao Q, Xue Y, Ren H, Wu L, Cheng Y, Li S et al: *Inhibition of endothelial cell proliferation and tumor angiogenesis by up-regulating NDRG2 expression in breast cancer cells.* PLoS One 2012, 7(2):e32368.

39. Li Z, Sun Y, Wan H, Chai F: [Overexpression of N-myc downstream regulated gene 2 (NDRG2) inhibits proliferation, migration and promotes apoptosis in SW480 rectal cancer cells]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2017, 33(1):48-52.

40. Yang CL, Zheng XL, Ye K, Ge H, Sun YN, Lu YF, Fan QX: *NDRG2 suppresses proliferation, migration, invasion and epithelial-mesenchymal transition of esophageal cancer cells through regulating the AKT/XIAP signaling pathway.* Int J Biochem Cell Biol 2018, 99:43-51.

41. Liu X, Niu T, Liu X, Hou W, Zhang J, Yao L: *Microarray profiling of HepG2 cells ectopically expressing NDRG2.* Gene 2012, 503(1):48-55.

42. Xie Q, Wang S, Zhao Y, Zhang Z, Qin C, Yang X: *MiR-519d impedes cisplatin-resistance in breast cancer stem cells by down-regulating the expression of MCL-1.* Oncotarget 2017, 8(13):22003-22013.

43. Xu YY, Wu TT, Zhou SH, Bao YY, Wang QY, Fan J, Huang YP: *Apigenin suppresses GLUT-1 and p-AKT expression to enhance the chemosensitivity to cisplatin of laryngeal carcinoma Hep-2 cells: an in vitro study.* Int J Clin Exp Pathol 2014, 7(7):3938-3947.

44. Yu PN, Yan MD, Lai HC, Huang RL, Chou YC, Lin WC, Yeh LT, Lin YW: *Downregulation of miR-29 contributes to cisplatin resistance of ovarian cancer cells.* Int J Cancer 2014, 134(3):542-551.

45. Liu J, Yang L, Zhang J, Zhang J, Chen Y, Li K, Li Y, Li Y, Yao L, Guo G: *Knock-
down of NDRG2 sensitizes cervical cancer Hela cells to cisplatin through suppressing Bcl-2 expression. BMC Cancer 2012, 12:370.

46. Park S, Oh SS, Lee KW, Lee YK, Kim NY, Kim JH, Yoo J, Kim KD: NDRG2 contributes to cisplatin sensitivity through modulation of BAK-to-Mcl-1 ratio. Cell Death Dis 2018, 9(2):30.

Figures

NDRG2 mRNA expression and protein levels in tissue samples and cell lines (A an
NDRG2 overexpression or silence in ovarian cancer cells (A) SKOV3, OVCAR-3, and CAOV3 cells were transfected with si-NC (negative control) or si-NDRG2, as confirmed by real-time PCR. **P<0.01.
Figure 3

Effects of NDRG2 on ovarian cancer cell proliferation SKOV3, OVCAR-3, and CAOV
Figure 4

Effects of NDRG2 on ovarian cancer cell apoptosis and cell cycle SKOV3, OVCAR-3
Figure 5

Effects of NDRG2 on ovarian cancer cell sensitivity to DDP treatment SKOV3, OVCAR-3, and CAOV3.